Sunday, 15 November 2026European Markets

ZENOBE GRAMME CERT Stock 12.64% Up Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - The Market ended the session with ZENOBE GRAMME CERT (ZEN.BR) rising 12.64% to €196.00 on Monday while BEL 20 rose 0.1% to €3,707.77.

ZENOBE GRAMME CERT's last close was €196.00, 12.46% below its 52-week high of €223.90.

About ZENOBE GRAMME CERT

Immo-Zenobe Gramme SA engages in the issuance of real estate certificates in Belgium. Immo-Zenobe Gramme SA is based in Molenbeek-Saint-Jean, Belgium. Immo-Zenobe Gramme SA operates as a subsidiary of KBC Bank NV.

Earnings Per Share

As for profitability, ZENOBE GRAMME CERT has a trailing twelve months EPS of €0.17.

PE Ratio

ZENOBE GRAMME CERT has a trailing twelve months price to earnings ratio of 1152.94. Meaning, the purchaser of the share is investing €1152.94 for every euro of annual earnings.

Volatility

ZENOBE GRAMME CERT's last week, last month's, and last quarter's current intraday variation average was 5.46%, 2.23%, and 5.40%.

ZENOBE GRAMME CERT's highest amplitude of average volatility was 7.18% (last week), 3.54% (last month), and 5.40% (last quarter).

Volume

Today's last reported volume for ZENOBE GRAMME CERT is 27 which is 18.18% below its average volume of 33.

More news about ZENOBE GRAMME CERT (ZEN.BR).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com